Cargando…

Targeted Delivery of Chemotherapeutic Agents for Osteosarcoma Treatment

Since osteosarcoma (OS) is an aggressive bone cancer with unknown molecular pathways of etiology and pathophysiology, improving patient survival has long been a challenge. The conventional therapy is a complex multidisciplinary management that include radiotherapy, chemotherapy which followed by sur...

Descripción completa

Detalles Bibliográficos
Autores principales: Xie, Duoli, Wang, Zhuqian, Li, Jie, Guo, De-an, Lu, Aiping, Liang, Chao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8931218/
https://www.ncbi.nlm.nih.gov/pubmed/35311145
http://dx.doi.org/10.3389/fonc.2022.843345
_version_ 1784671208864743424
author Xie, Duoli
Wang, Zhuqian
Li, Jie
Guo, De-an
Lu, Aiping
Liang, Chao
author_facet Xie, Duoli
Wang, Zhuqian
Li, Jie
Guo, De-an
Lu, Aiping
Liang, Chao
author_sort Xie, Duoli
collection PubMed
description Since osteosarcoma (OS) is an aggressive bone cancer with unknown molecular pathways of etiology and pathophysiology, improving patient survival has long been a challenge. The conventional therapy is a complex multidisciplinary management that include radiotherapy, chemotherapy which followed by surgery and then post-operative adjuvant chemotherapy. However, they have severe side effects because the majority of the medicines used have just a minor selectivity for malignant tissue. As a result, treating tumor cells specifically without damaging healthy tissue is currently a primary goal in OS therapy. The coupling of chemotherapeutic drugs with targeting ligands is a unique therapy method for OS that, by active targeting, can overcome the aforementioned hurdles. This review focuses on advances in ligands and chemotherapeutic agents employed in targeted delivery to improve the capacity of active targeting and provide some insight into future therapeutic research for OS.
format Online
Article
Text
id pubmed-8931218
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-89312182022-03-19 Targeted Delivery of Chemotherapeutic Agents for Osteosarcoma Treatment Xie, Duoli Wang, Zhuqian Li, Jie Guo, De-an Lu, Aiping Liang, Chao Front Oncol Oncology Since osteosarcoma (OS) is an aggressive bone cancer with unknown molecular pathways of etiology and pathophysiology, improving patient survival has long been a challenge. The conventional therapy is a complex multidisciplinary management that include radiotherapy, chemotherapy which followed by surgery and then post-operative adjuvant chemotherapy. However, they have severe side effects because the majority of the medicines used have just a minor selectivity for malignant tissue. As a result, treating tumor cells specifically without damaging healthy tissue is currently a primary goal in OS therapy. The coupling of chemotherapeutic drugs with targeting ligands is a unique therapy method for OS that, by active targeting, can overcome the aforementioned hurdles. This review focuses on advances in ligands and chemotherapeutic agents employed in targeted delivery to improve the capacity of active targeting and provide some insight into future therapeutic research for OS. Frontiers Media S.A. 2022-03-04 /pmc/articles/PMC8931218/ /pubmed/35311145 http://dx.doi.org/10.3389/fonc.2022.843345 Text en Copyright © 2022 Xie, Wang, Li, Guo, Lu and Liang https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Oncology
Xie, Duoli
Wang, Zhuqian
Li, Jie
Guo, De-an
Lu, Aiping
Liang, Chao
Targeted Delivery of Chemotherapeutic Agents for Osteosarcoma Treatment
title Targeted Delivery of Chemotherapeutic Agents for Osteosarcoma Treatment
title_full Targeted Delivery of Chemotherapeutic Agents for Osteosarcoma Treatment
title_fullStr Targeted Delivery of Chemotherapeutic Agents for Osteosarcoma Treatment
title_full_unstemmed Targeted Delivery of Chemotherapeutic Agents for Osteosarcoma Treatment
title_short Targeted Delivery of Chemotherapeutic Agents for Osteosarcoma Treatment
title_sort targeted delivery of chemotherapeutic agents for osteosarcoma treatment
topic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8931218/
https://www.ncbi.nlm.nih.gov/pubmed/35311145
http://dx.doi.org/10.3389/fonc.2022.843345
work_keys_str_mv AT xieduoli targeteddeliveryofchemotherapeuticagentsforosteosarcomatreatment
AT wangzhuqian targeteddeliveryofchemotherapeuticagentsforosteosarcomatreatment
AT lijie targeteddeliveryofchemotherapeuticagentsforosteosarcomatreatment
AT guodean targeteddeliveryofchemotherapeuticagentsforosteosarcomatreatment
AT luaiping targeteddeliveryofchemotherapeuticagentsforosteosarcomatreatment
AT liangchao targeteddeliveryofchemotherapeuticagentsforosteosarcomatreatment